Notably, combined immunotherapy with CD47- and IL-6-blocking agents has been shown to reverse fibrotic conditions in mice, suggesting new therapeutic alternatives for treating pulmonary fibrosis [18, 54]. This evidence concerns the gene IL6 and pulmonary fibrosis.